Dr Nabil Saba on Optimizing Anaplastic Thyroid Cancer Outcomes

Dr Nabil Saba emphasizes that while systemic therapy has revolutionized the treatment of anaplastic thyroid cancer (ATC), surgical resection remains a foundational element of management for patients with resectable disease. For the community oncologist, the most critical immediate step in the workup—prior to initiating systemic therapy—is the rapid determination of the patient’s BRAF mutation status.

A sizable portion of ATC patients harbor genomic alterations, and identifying a BRAF V600E mutation is a clinical game-changer. This information dictates the selection of targeted therapies, which have significantly improved outcomes in both resectable and non-resectable settings. Dr. Saba stresses that ATC is an aggressive disease where delays can be detrimental. If a community center cannot provide rapid genomic testing or immediate surgical and multidisciplinary intervention, the patient should be transitioned to a specialized center without delay.

While recent ASCO guidelines focus heavily on the evolving role of systemic agents like BRAF/MEK inhibitors, Dr. Saba reminds clinicians that these treatments must be integrated into a multimodal approach. The speed of the initial workup—specifically genomic profiling and surgical evaluation—is the primary factor in mitigating the risk of delayed, crucial treatments that these patients desperately need.